RxDoctor Payments Data

Ross Podell, MD

Internal Medicine · Paoli, PANPI 1285663187

Payments from drug & device makers

$2,692in general payments, 2019–2025

Across 169 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$553
  • Amarin Pharma, Inc.$381
  • Lilly USA, LLC$346
  • AbbVie$332
  • AstraZeneca$288
  • Pfizer$152
  • plus $639 from 16 others

What the payments were for

  • Food & beverage$2,63398%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,692 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,814
Medicare patients
273
Services billed
2,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban33$38,580
EliquisApixaban27$25,008
FarxigaDapagliflozin Propanediol14$22,587
JardianceEmpagliflozin13$19,353
JanuviaSitagliptin Phosphate14$18,747
OzempicSemaglutide15$13,799
MyrbetriqMirabegron13$6,082
Breo ElliptaFluticasone/Vilanterol13$5,134
Venlafaxine Hcl ErVenlafaxine Hcl19$4,338
Rosuvastatin Calcium243$4,142
Atorvastatin Calcium230$3,605
ArexvyRsvpref3 Antigen/As01e/Pf11$3,466
Ezetimibe90$2,834
SynthroidLevothyroxine Sodium18$1,781
Metoprolol Succinate80$1,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$84$38,58033 claims
PfizerEliquis$152$25,00827 claims
AstraZenecaFarxiga$288$22,58714 claims
Boehringer IngelheimJardiance$53$19,35313 claims
MerckJanuvia$41$18,74714 claims
Novo NordiskOzempic$85$13,79915 claims
GSKBreo Ellipta, Arexvy$553$8,60024 claims
AbbVieSynthroid$332$1,78118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →